We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$347M
AUM Growth
-$92.7M
Cap. Flow
-$125M
Cap. Flow %
-36.15%
Top 10 Hldgs %
71.88%
Holding
54
New
11
Increased
5
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.29M
2
A icon
Agilent Technologies
A
+$5.96M
3
ICLR icon
Icon
ICLR
+$5.89M
4
CNC icon
Centene
CNC
+$4.47M
5
RGEN icon
Repligen
RGEN
+$4.23M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$42.6M
2
NTRA icon
Natera
NTRA
+$12.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
4
DHR icon
Danaher
DHR
+$8.29M
5
MDT icon
Medtronic
MDT
+$8.06M

Sector Composition

Rank Sector Weight
1 Healthcare 98.84%
2 Consumer Staples 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WAT icon
26
Waters Corp
WAT
$36.4B
$3.08M 0.89%
+8,100
New +$2.98M
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.35B
$2.86M 0.82%
106,900
-37,100
-26% -$887K
GMAB icon
28
Genmab
GMAB
$17.7B
$2.83M 0.82%
92,000
-156,100
-63% -$4.87M
NTRA icon
29
Natera
NTRA
$37B
$2.7M 0.78%
11,800
-58,600
-83% -$12.2M
IMUX icon
30
Immunic
IMUX
$188M
$2.51M 0.72%
469,941
– –
ACHC icon
31
Acadia Healthcare
ACHC
$2.99B
$2.4M 0.69%
+169,000
New +$3.2M
ITGR icon
32
Integer Holdings
ITGR
$3.38B
$2.34M 0.67%
+29,800
New +$2.37M
ELVN icon
33
Enliven Therapeutics
ELVN
$3.77B
$2.16M 0.62%
140,300
– –
PVLA
34
Palvella Therapeutics
PVLA
$2.03B
$2.02M 0.58%
+19,300
New +$1.65M
HQY icon
35
HealthEquity
HQY
$8.28B
$1.55M 0.45%
16,900
-8,400
-33% -$804K
SCYX icon
36
SCYNEXIS
SCYX
$35.5M
$1.32M 0.38%
260,208
-158,608
-38% -$863K
IQV icon
37
IQVIA
IQV
$35.6B
$992K 0.29%
+4,400
New +$957K
KPTI icon
38
Karyopharm Therapeutics
KPTI
$161M
$990K 0.29%
134,566
– –
CORT icon
39
Corcept Therapeutics
CORT
$9.78B
$766K 0.22%
+22,000
New +$1.73M
ABBV icon
40
AbbVie
ABBV
$454B
– –
-19,800
Closed -$4.58M
AKRO
41
DELISTED
Akero Therapeutics
AKRO
– –
-40,500
Closed -$1.92M
ARQT icon
42
Arcutis Biotherapeutics
ARQT
$3.48B
– –
-214,400
Closed -$4.04M
ARVN icon
43
Arvinas
ARVN
$530M
– –
-698,363
Closed -$5.95M
ASND icon
44
Ascendis Pharma A/S
ASND
$16.6B
– –
-14,500
Closed -$2.88M
BEAM icon
45
Beam Therapeutics
BEAM
$2.58B
– –
-112,000
Closed -$2.72M
BMY icon
46
Bristol-Myers Squibb
BMY
$128B
– –
-257,600
Closed -$11.6M
EXAS
47
DELISTED
Exact Sciences
EXAS
– –
-73,600
Closed -$4.03M
IMRX icon
48
Immuneering
IMRX
$282M
– –
-90,900
Closed -$636K
JNJ icon
49
Johnson & Johnson
JNJ
$641B
– –
-26,800
Closed -$4.97M
UNH icon
50
UnitedHealth
UNH
$379B
– –
-17,800
Closed -$6.15M
1
2
3

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2025 Portfolio in Review

As of Q4 2025, Avidity Partners Management held 54 positions worth $347M, down 21% from $439M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Avidity Partners Management withdrew a net $125M in Q4 2025, closing 15 positions and reducing 19 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $11.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

Against the trend, Avidity Partners Management opened a new position in Alnylam Pharmaceuticals worth $8.35M.

  • Avidity Partners Management's largest Q4 2025 buy was Alnylam Pharmaceuticals: 21,000 shares worth $8.35M.
  • Avidity Partners Management added most to Repligen in Q4 2025, an estimated $4.23M increase.
  • Avidity Partners Management's biggest Q4 2025 reduction was Dianthus Therapeutics, cutting an estimated $42.6M.
  • Avidity Partners Management fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $11.6M.
  • Avidity Partners Management's ten largest holdings make up 72% of its $347M portfolio in Q4 2025.
  • Avidity Partners Management opened 11 new positions and closed 15 in Q4 2025.
  • Avidity Partners Management's portfolio value fell 21% quarter-over-quarter to $347M.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.